“An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) Module A – Post-Chemotherapy Urothelial and NonUrothelial Carcinoma of the Urinary Tract (hereinafter Study)” Durvalumab (hereinafter Study Drug)”

Sponsor
AstraZeneca

Protocol Number
AstraZeneca D4191C00068

To Learn More Call
201-510-0910